This website uses cookies to measure and enhance the website's performance. More information on cookies, how they are used and ViiV's cookies policy can be found here


This website is for residents of the UK and Ireland only

Select which site to enter

  • Healthcare professionals

    Resources to support your daily practice with dolutegravir. Important notice: This site is intended for healthcare professionals. By entering this site, you are confirming that you are a healthcare professional in the UK or Republic of Ireland

  • Press

    Resources for journalists and analysts, including press releases and media contacts for ViiV Healthcare

  • Patients and Carers

    Access general information about HIV and specific information for patients who have been prescribed dolutegravir, an integrase inhibitor approved for the treatment of HIV-1, or a dolutegravir-containing regimen

  • Members of the public

    General information about dolutegravir, a treatment for HIV-1, and dolutegravir-containing regimens


This medicine is subject to additional monitoring. This will allow quicker identification of new safety information. You can help by reporting any side effects you may get. See for how to report side effects. Alternatively, please use the link provided at the top of this page.

ViiV Healthcare logo

© ViiV Healthcare group of companies 2014. All rights reserved.
TIVICAY and TRIUMEQ are registered trademarks of the ViiV Healthcare group of companies.
UK/TRIM/0045/14a; Date of Preparation: October 2014

ViiV Healthcare UK Limited. Registered in England. Company number: 06990358 registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.

You are now leaving the site. ViiV Healthcare does not recommend, endorse or accept responsibility for sites controlled by third parties.